We showed that clinically relevant subtypes of patient tumours, across many cancer types, could be achieved by simply dividing the tumours into two categories based entirely on the expression of ELF4: those tumours which express high ELF4 levels and those that express low ELF4 levels. This evidence concerns the gene ELF4 and cancer.